Savara Inc.

NASDAQ: SVRA · Healthcare · Biotechnology

PublicHQ Langhorne, TXCIK 0001160308Reports USD

#973 of 1,394 Healthcare companies by revenue

EA Score

50D

FH 39DQ 64GM —SS 61

v0.1 · 55/100 weight · provisional

↑ Altman-Z, market scale · ↓ Piotroski F, operating margin

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$118.8M

Employees

Market cap

$1.3B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$257.0k$257.0k2020

Net income-$118.8M-$118.8M2025

Operating income-$123.5M-$123.5M2025

Total assets$253.4M$253.4M2025

Liabilities$50.3M$50.3M2025

Equity$203.1M$203.1M2025

Revenue trend

FY2013 – FY2020 · USD

$2.1M

FY13

FY14

FY15

$45.0k

FY16

$128.0k

FY16

FY17

FY19

$257.0k

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Savara Inc. booked $257.0k in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -46240.1% net margin.

Peers · Healthcare

Corvus Pharmaceuticals, Inc.——MeiraGTx Holdings plc49D IRadimed Corporation86A Enovis Corporation66B

Key facts

CEOMatthew Pauls

SectorHealthcare

IndustryBiotechnology

HeadquartersLanghorne, TX

ExchangeNASDAQ: SVRA

Employees59

IPO date2017-04-28

Latest filings

8-K2026-06-08 10-Q2026-05-12 DEF 14A2026-04-24 8-K2026-03-13 10-K2026-03-13 8-K2026-01-27 8-K2026-01-09 10-Q2025-11-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.